(Q56828539)

English

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

0 references

title

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing (English)

0 references

Lars L. Gustafsson

2

0 references

author name string

Brian Godman

series ordinal

1

0 references

publication date

16 January 2013

0 references

published in

Applied Health Economics and Health Policy

0 references

volume

11

0 references

issue

1

0 references

page(s)

79-82

0 references

cites work

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Forecasting drug utilization and expenditure in a metropolitan health region

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Potential savings without compromising the quality of care

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

How much will Herceptin really cost?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Balancing Big Pharma's books

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

International variability in the reimbursement of cancer drugs by publically funded drug programs

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40258-012-0008-7

retrieved

21 January 2018

Identifiers

DOI

10.1007/S40258-012-0008-7

0 references

PubMed publication ID

23322546

0 references

(Q56828539)

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)